17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS 1143516-05-5

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1143516-05-5

Name

17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid

Syn­onyms

1143516-05-5 [RN]
17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oic acid
17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-säure [Ger­man] [ACD/IUPAC Name]
2-[2-[2-[[2-[2-(2-Aminoethoxy)ethoxy]acetyl]amino]ethoxy]ethoxy]acetic acid
20802384 [Beil­stein]
3,6,12,15-Tetraoxa-9-azaheptadecan-1-oic acid, 17-amino-10-oxo- [ACD/​Index Name]
Acide 17-amino-10-oxo-3,6,12,15-tétraoxa-9-azaheptadécan-1-oïque [French] [ACD/IUPAC Name]
Z2O2O1VM2O2O1VQ [WLN]
[2-(2-{2-[2-(2-AMINOETHOXY)ETHOXY]ACETAMI­DO}ETHOXY)ETHOXY]ACETIC ACID
2-[2-(2-{2-[2-(2-AMINOETHOXY)ETHOXY]ACETAMI­DO}ETHOXY)ETHOXY]ACETIC ACID
Aeea-aeea
H-AEEA-AEEA
H-AEEA-AEEA-OH
MFCD13184942 [MDL number]

SMILES

C(COC­COCC(=O)NCCOC­COCC(=O)O)N

Std­InChI

InChI=1S/C12H24N2O7/c13-1-3-18-5-7-20-9-11(15)14-2-4-19-6-8-21-10-12(16)17/h1-10,13H2,(H,14,15)(H,16,17)

Std­InChIKey

YQZVQKYXW­PIK­IX-UHF­F­­FAOYSA-N

Mol­e­c­u­lar Formula

C₁₂H₂₄N₂O₇

Mol­e­c­u­lar Weight

308.328

MDL Number

MFCD13184942

Prop­er­ties

Appear­ance

Pow­der

Struc­ture

Safe­ty Data

Sym­bol

GHS07

Sig­nal Word

Warn­ing

Haz­ard statements

Pre­cau­tion­ary Statements

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Iden­ti­fi­ca­tion Methods

HPLC

Puri­ty

98% min

Shelf Life

1 year

Stor­age

Stor­age at 2~8°, Away from light.

Known Appli­ca­tion

As an inter­me­di­ate in the syn­the­sis of semaglu­tide, 17-amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic acid like­ly plays a cru­cial role in the pro­duc­tion of this med­ica­tion. Semaglu­tide is a glucagon-like pep­tide-1 (GLP-1) recep­tor ago­nist used in the treat­ment of type 2 diabetes. 

1.Using this inter­me­di­ate in the syn­the­sis of semaglu­tide can allow for greater con­trol over the puri­ty and qual­i­ty of the final prod­uct. Inter­me­di­ate com­pounds are often puri­fied at each step of the syn­the­sis, help­ing to remove impurities. 

2.And devel­op­ing an effi­cient syn­the­sis route with this inter­me­di­ate could con­tribute to the cost-effec­­tive­­ness of pro­duc­ing semaglutide.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (http://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.